<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842191</url>
  </required_header>
  <id_info>
    <org_study_id>FOMS</org_study_id>
    <nct_id>NCT01842191</nct_id>
  </id_info>
  <brief_title>Efficacy of Fish Oil in Multiple Sclerosis</brief_title>
  <acronym>EFOMS</acronym>
  <official_title>Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <authority>Mexico: Coordinación de Investigación en Salud</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present work was to evaluate the efficacy of fish oil supplementation on
      serum proinflammatory cytokines levels, oxidative stress markers and disease progression in
      MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current research findings suggest that Omega-3 polyunsaturated fatty acids (PUFA) such as
      eicosahexanoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have
      anti-inflammatory, antioxidant and neuroprotective effects. The aim of the present work was
      to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokines
      levels, oxidative stress markers and disease progression in MS. 50 patients with
      relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish
      oil for 12 months. The primary outcome was serum TNFα levels; Secondary outcomes were IL-1β,
      IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status
      scale (EDSS) and annualized relapses rate (ARR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>TNF alpha</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum TNF alpha levels, at baseline, 3, 6, 9 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-1 beta, IL-6, Lipoperoxides, nitric oxide</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum IL-1 beta, IL-6, Lipoperoxides, nitric oxide levels at baseline, 3, 6, 9 and 12 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS) and Annualized rate of relapses (ARR)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>EDSS and ARR at baseline, 6 months and 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Relapsing- Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>PUFAS</other_name>
    <other_name>Omega 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients had clinically definite and magnetic resonance image supported MS

          -  Had at least one relapse in the year before entry into the study

          -  EDSS score of 0-5

          -  Treated with subcutaneous 250 μg interferon beta-1b (Betaseron, Bayer)

        Exclusion Criteria:

          -  they were taking another supplement

          -  had progressive forms of MS

          -  had history of severe depression

          -  had history of acute liver or renal dysfunction

          -  had history of tobacco, drug or alcohol abuse

          -  had intolerance, contraindication or allergy to fish oil
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genaro G Ortiz, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Social Security Mexican Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMSS, Specialties Hospital, Neurology Departament</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35-9. doi: 10.3233/DMA-2009-0602.</citation>
    <PMID>19242067</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 20, 2013</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Genaro Gabriel Ortiz</investigator_full_name>
    <investigator_title>Investigador titular D</investigator_title>
  </responsible_party>
  <keyword>R-R MS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
